[HTML][HTML] Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly …

JH Sampson, AB Heimberger, GE Archer… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
JH Sampson, AB Heimberger, GE Archer, KD Aldape, AH Friedman, HS Friedman…
Journal of clinical oncology, 2010ncbi.nlm.nih.gov
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III
(EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal
tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms.
Abstract
Purpose
Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms.
ncbi.nlm.nih.gov